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Abstract
Pre-diabetes is a serious health problem in the United States. Distinguished by plasma
glucose levels that are above the normal threshold, patients with pre-diabetes are 10 times more
likely to develop type 2 diabetes. Patients with pre-diabetes suffer the same complications as
patients with diabetes including diabetic retinopathy, nephropathy, and microalbuminuria.
There is considerable evidence to support the idea that early identification and aggressive
treatment of pre-diabetes has the potential to delay disease progression. The American Diabetes
Association’s clinical practice guideline recommends management of with lifestyle modification
and metformin for patients who are at risk for developing type 2 diabetes. The purpose of this
project was to evaluate the implementation of the 2012 ADA clinical practice guidelines
regarding the management of patients with pre-diabetes by the health care providers at a
volunteer-run clinic located in a large metropolitan area in the southeastern United States.
This study, even with a small sample size (n=26) revealed that the providers at the clinic
had not implemented the 2012 ADA clinical practice guidelines. Clinical practice guidelines
promote health care interventions that have proven benefits and improve the consistency of care
provided to patients. The greatest benefits of implementing clinical practice guidelines for
patients with pre-diabetes are early diagnosis and aggressive disease management. This would
improve patient outcomes and in the long run, decrease the cost of medical care.

Keywords: pre-diabetes, clinical practice guidelines, impaired fasting glucose, impaired glucose
tolerance, metformin, pharmacologic intervention, prevention of type 2 diabetes

Chapter One: Introduction
Pre-diabetes is a precursor to diabetes and is a public health epidemic in the United States (Centers
for Disease Control and Prevention [CDC], 2011). Diabetes develops insidiously, during which time
glucose metabolism progresses from normal to pre-diabetes, then to diabetes (Rhee et al., 2010). Although
most patients with pre-diabetes experience no symptoms, it, like diabetes, has the potential for significant
morbidity and mortality. This chapter provides an overview of pre-diabetes, discusses the extent and
significance of the problem, and describes the current standards of care in pre-diabetes management. It
concludes with the clinical problem, purpose of project, and an operational definition of terms.
Background
Pre-diabetes is one of the most common medical conditions encountered in primary care (Fonseca,
2007; O’Mara, 2008). This chronic condition is distinguished by plasma glucose or glycosylated
hemoglobin (HbA1C) levels that are above the normal threshold (American Diabetes Association [ADA],
2012; Fonseca, 2007; O’Mara, 2008). Pre-diabetes includes impaired fasting glucose (IFG), impaired
glucose tolerance (IGT), and a combination of both IGT and IFG (ADA, 2012; Aroda & Ratner, 2008;
CDC, 2011; Fonseca, 2007; World Health Organization [WHO], 2006). The WHO and International
Diabetes Federation defines IFG as a fasting plasma glucose (FPG) between 110 mg/dL and 126 mg/dL,
and IGT as a FPG less than 126 mg/dL and blood glucose levels between 140 mg/dL and 200 mg/dL two
hours after a 75 gram glucose drink (WHO, 2006). The American Diabetes Association uses slightly lower
criteria in the diagnosis of pre-diabetes (ADA, 2012). Associated laboratory values for pre-diabetes
include FPG levels between 100 mg/dL and 125 mg/dL, postprandial blood glucose levels between 140
mg/dL and 199 mg/dL two hours after a 75 gram oral glucose load on a two hour oral glucose tolerance test
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(2h OGTT), or a HbA1C range of 5.7 to 6.4% (ADA, 2012; Biuso, Butterworth, & Linden, 2007; Fonseca,
2007; Pagana & Pagana, 2011). Table 1 presents a comparison of the laboratory tests, values and
associated pre-diabetic conditions according to the ADA and WHO.
Table 1
Comparison of Pre-Diabetes Laboratory Values by Health Organization
Pre-Diabetic
Condition
IFG
IGT

Laboratory
Test
FPG
FPG
2h OGTT
HbA1c

Diagnostic Laboratory Values`
ADA
WHO
100-125 mg/dL
110-125 mg/dL
<126 mg/dL
--140-199 mg/dL
>140 and <200 mg/dL
5.7-6.4%
Not recommended

Pre-Diabetes
(IFG/IGT)
Note. Adapted from “Standards of Medical Care in Diabetes – 2012” by American Diabetes Association,
2012, Diabetes Care, 35(Supplement 1), p. S16. Copyright 2012 by the American Diabetes Association.
Adapted from “Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia” by World
Health Organization, 2006, Geneva, Switzerland: World Health Organization, p. 3. Copyright 2006 by the
World Health Organization.

Prevalence of Pre-Diabetes and Diabetes
The prevalence of diabetes continues to grow exponentially. Diabetes was the seventh leading
cause of death in the United States in 2007 and the risk of death among people with diabetes is nearly
double that of people of similar age who do not have diabetes (CDC, 2011). In 2011, approximately 79
million, or 26%, of U.S. adults over 20 years of age had pre-diabetes (CDC, 2011; Cowie et al., 2009). The
latest data from the Centers’ for Disease Control (CDC) (2011) indicate that nearly 35% of non-Hispanic
whites, 35% of non-Hispanic blacks, and 36% of Mexican Americans have pre-diabetes.
Currently there are no data for the prevalence of pre-diabetes in the state of Florida or Duval
County. Data regarding diabetes, however, are suggestive that pre-diabetes is also a state and local
problem as the prevalence of Floridians with diabetes increased by 57.4% from 1999 to 2009 (Florida
Department of Health, Bureau of Epidemiology [Florida DOH], 2011). According to self-reported
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Behavioral Risk Factor Surveillance System (BRFSS) surveys, 10.7% of Florida adults have diabetes,
which is approximately 1.5 million residents (Florida DOH, 2011). The most recent data from the BRFSS
indicate that 9.5% of non-Hispanic whites, 13.5% of non-Hispanic blacks, and 12.1% of Hispanics living in
Florida have diabetes (Florida DOH, 2011).
Diabetes and its complications are substantial causes of morbidity and mortality, reduced quality of
life, and economic loss (CDC, 2011; Cowie et al., 2009). The annual financial burden of diabetes in the
U.S. exceeds $174 billion. The average medical expenditure for patients with diabetes is 2.3 times higher
than those without diabetes (CDC, 2011).
Patients with pre-diabetes are 10 times more likely to develop type 2 diabetes (Rhee et al., 2010).
These patients also suffer the same complications and comorbidities as patients with diabetes (ADA, 2012;
Milman & Crandall, 2011; Rhee et al., 2010). Evidence suggests even slight elevations in plasma glucose
levels are associated with concomitant diabetic retinopathy, nephropathy, and microalbuminuria (Aroda &
Ratner, 2008; Milman & Crandall, 2011, Ngatena & Kapustin, 2011; Parikh et al., 2010). Other
comorbidities associated with pre-diabetes include atherosclerosis, peripheral vascular disease,
hyperlipidemia, cardiovascular disease, and stroke (ADA, 2012; Fonseca, 2007; Salyers, 2011; Scheen,
2007; WHO, 2006).
Standards of Care
Early identification and aggressive treatment of persons with pre-diabetes has the potential to
minimize disease progression and delay the onset of comorbidities associated with diabetes (ADA, 2012;
CDC, 2012; Ngatena & Kapustin, 2011; Yuen, Sugeng, & Weiland, 2010). The primary goal of clinical
management of pre-diabetes is to help the body to use insulin properly while preventing or delaying the
onset of overt type 2 diabetes. “The Standards of Medical Care in Diabetes – 2012,” the ADA’s clinical
practice guideline (CPG), recommends clinical management of pre-diabetes with lifestyle modification
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(LSM) and metformin (ADA, 2012). Pharmacotherapy with metformin is recommended as first line
treatment for those at very-high-risk for developing type 2 diabetes. This includes patients with a history
of gestational diabetes (GDM), patients who are obese, and those with severe or progressive hyperglycemia
(ADA, 2012). Table 2 depicts the recommendations for the management of patients with metformin to
prevent or delay progression to type 2 diabetes.
Table 2
Recommendations for the Management of Patients with Metformin
Risk Factor or Medical Condition
-Patients with IGT
-Patients with IFG
-Patients with a HbA1c of 5.7-6.4%
-Body mass index (BMI) >35 kg/m2 a
-Age >60 years *
-Women with prior diagnosis of gestational diabetes mellitusa
Note. Adapted from “Standards of Medical Care in Diabetes – 2012” by American Diabetes Association,
2012, Diabetes Care, 35(Supplement 1), p. S16. Copyright 2012 by the American Diabetes Association.
a
Metformin should be considered especially if these patients have IGT, IFG, or HbA1c 5.7-6.4%

Abbreviated Literature Review
Several studies and clinical reviews have examined the efficacy of various pharmacologic agents in
preventing type 2 diabetes (Knowler et al., 2002; Lily & Godwin, 2009; Salpeter, 2008; Yuen et al., 2010).
Metformin, however, is currently the only pharmacologic therapy recommended for the treatment of prediabetes (ADA, 2012). Evidence has found that metformin was as effective as LSM in preventing type 2
diabetes in patients with a history of GDM and those patients with a BMI index of 35 kg/m2 or greater
(ADA, 2012; Knowler et al., 2002).
Problem
The health clinic utilized for this project provides free primary care and preventive medical services
to the working uninsured in Jacksonville, Florida. Chronic and acute conditions such as asthma, chronic
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obstructive pulmonary disease, hypertension, hyperlipidemia, diabetes, coronary artery disease, upper
respiratory infections, and pneumonia are managed through diagnosis, education, and medications. The
ADA’s clinical practice guidelines regarding the management of diabetes are updated and published in
January of each year. This provided an opportunity to evaluate the practices of health care providers at the
clinic regarding the implementation of the 2012 ADA standards of care for the management of patients
with pre-diabetes in the clinic. The PICO statement for this project is: (P) Did health care practitioners
providing primary care services at a clinic for the working uninsured (O) adhere to the (C) 2012 ADA
clinical practice guidelines for the management of patients with pre-diabetes six months after (I) they were
published?
Project Purpose
The purpose of this project was to evaluate the implementation of the 2012 ADA clinical practice
guidelines regarding the management of patients with pre-diabetes by the health care providers at a clinic
for the working uninsured. Specifically this project evaluated if health care providers implemented the
2012 ADA standards of care when managing patients with pre-diabetes using lifestyle modification,
medication, or a combination of both.
Project Description
The paradigm of evidence-based practice served as the framework for this project.
Evidence-based practice is the diligent, precise, and thoughtful use of the best evidence when making
decisions and providing care to patients (Melnyk & Fineout-Overholt, 2011). This practice requires the
health care practitioner to integrate clinical expertise with the best relevant, clinical evidence while
considering the individual preferences of the patient (Melnyk & Fineout-Overholt, 2011; Sackeit,
Rosenberg, Muir-Gray, Haynes, & Richardson, 1996).
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This project utilized a retrospective analysis to evaluate provider practice regarding the management of
patients with pre-diabetes starting six months after the publication of the guidelines. The outcome measure
was implementation of the 2012 ADA standards of care for patients with pre-diabetes.
Definition of Terms
Fasting Plasma Glucose (FPG)
A laboratory test that measures the amount of glucose in a person’s blood plasma after a period,
usually eight hours, of fasting. This test is used to screen for pre-diabetes and diabetes (Pagana & Pagana,
2011).
Gestational Diabetes (GDM)
High blood sugar or diabetes that starts or is first diagnosed during pregnancy. This condition
usually occurs approximately half way through the pregnancy. Pregnant women are screened between the
24th and 28th week of pregnancy for this condition (ADA, 2012).
Hemoglobin A1c (HbA1c)
A laboratory test that measures the amount of glucose attached to hemoglobin. It is used to
diagnose and monitor pre-diabetes and diabetes treatment. This test reflects the amount of glucose
available in the blood stream over a red blood cell’s 120 day life span. This test is also used to assess
blood glucose control over a three to four month period (Pagana & Pagana, 2011).
Impaired Fasting Glucose (IFG)
A pre-diabetic state in which the fasting blood glucose level is consistently elevated above the
normal level, however, it is not high enough to be diagnosed as diabetes mellitus. The ADA criterion
defines IFG as having fasting glucose levels 100 mg/dL and 125 mg/dL (ADA, 2012).
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Impaired Glucose Tolerance (IGT)
A pre-diabetic state of hyperglycemia where the glucose level is elevated after a two hour oral
glucose load, however the glucose level does not meet criteria for type 2 diabetes mellitus. A two-hour
glucose level of 140 to 199 mg/dL on the 75-g oral glucose tolerance test is considered IGT (ADA, 2012).
Lifestyle Modification (LSM)
Activities such as improved diet and nutrition, weight management, and exercise aimed at
preventing diabetes and improving plasma glucose levels in patients with pre-diabetes (ADA, 2012).
Metformin
The oral diabetic medication in the biguanide class that is approved for use in the United States. It
is the first-line drug of choice for the treatment of pre-diabetes. Metformin works by suppressing glucose
production and improving insulin action in the liver (Rizza & Vella, 2009).
2 Hour Oral Glucose Tolerance Test (2h OGTT)
Referred to as the glucose tolerance test, this laboratory assay measures the body’s ability to
metabolize glucose. The test can be used to diagnose pre-diabetes, diabetes, or gestational diabetes
(Pagana & Pagana, 2011).
Pre-Diabetes
For the purposes of this study, the ADA (2012) criteria was used for the diagnosis of pre-diabetes
(see Table 3).
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Table 3
ADA Diagnostic Criteria for Pre-Diabetes
Diagnostic Test
Laboratory Value
FPG
100-125 mg/dL
2h OGTT
140-199 mg/dL
HbA1c
5.7-6.4%
Note. Adapted from “Standards of Medical Care in Diabetes – 2012” by American Diabetes Association,
2012, Diabetes Care, 35(Supplement 1), p. S16. Copyright 2012 by the American Diabetes Association.

Type 2 Diabetes
A chronic disease in which there are elevated levels of glucose in the blood. Type 2 diabetes is the
most common form of diabetes (ADA, 2012).
Working Uninsured Population
Persons who are employed and live in or work an average of 20 hours per week in Duval County or
Jacksonville, Florida , and have an income of 1.5 times the poverty level or hold no health insurance.
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Chapter Two: Review of Literature
This chapter provides an overview of the literature sources and search strategies that were used to
locate and retrieve the best evidence regarding the pharmacologic management of pre-diabetes with
metformin. This is followed by a discussion of the evidence regarding the use of HbA1c in the diagnosis
and management of pre-diabetes. Next the ADA clinical practice recommendations will be analyzed using
the Appraisal of Guidelines for Research and Evaluation II (AGREE II) Instrument. This chapter
concludes with a synthesis and discussion of the evidence regarding the use of metformin and LSM in the
treatment of pre-diabetes.
Literature Sources and Search Strategies
For this review, the following databases were searched: UNF One Search, OVID, Medline, and
Cochrane. The following terms were used in various combinations to search the above databases: ADA
clinical practice recommendations, impaired fasting glucose, impaired glucose tolerance, pre-diabetes,
metformin, prevention of type 2 diabetes, pharmacological intervention, and HbA1c. The initial search
yielded 76,099 articles. Searches were then limited to the years 2002 to 2012, the English language, metaanalyses, and randomized controlled trials that were conducted with human subjects investigating the
treatment of pre-diabetes with metformin or LSM. A manual search of citations for duplicate articles,
seminal studies, and relevant review articles was conducted. The search was then updated through an
examination of references from the RCT and meta-analyses. The final search yielded four recent metaanalyses, one CPG, and one randomized controlled trial (RCT).
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HbA1c in the Diagnosis and Management Pre-Diabetes
In the past, pre-diabetes and diabetes were diagnosed exclusively using the FPG and OGTT. The
HbA1c, however, has emerged as a reliable and convenient tool in assessing plasma glucose levels. The
ADA now recommends using the HbA1c in the diagnosis and management of patients with pre-diabetes
(ADA, 2012; Tankova, Chakarova, Dakovska, & Atanassova, 2011). The use of HbA1c has some
advantages over FPG and OGTT testing. It does not require fasting or special scheduling. The HbA1c also
provides a clearer representation of chronic hyperglycemia and is more closely associated with the comorbidities associated with diabetes (Bonora & Tuomiletho, 2011; Buell, Kermah, & Davidson, 2007;
Olson, Rhee, Herrick, & Ziemer, 2010; Tankova et al., 2011).
The HbA1c assay is as precise, if not more accurate, in diagnosing and managing patients with prediabetes than the FPG and the OGTT. A study conducted by Silverman et al. (2011) confirmed the ADA
standard of a HbA1c of 5.7% as the optimal cutoff for pre-diabetes. This study found that a HbA1c of
5.7% yielded a sensitivity of 54.8%, a specificity of 71.3%, a positive predictive value of 51.4, and a
negative predictive value of 74.1 (Silverman et al., 2011). A review of the 1999-2004 National Health and
Nutrition Examination Survey (NHANES) data also found that a HbA1c of 5.8% has a sensitivity of 86%
and a specificity of 92% for diagnosing pre-diabetes (Buell et al., 2007; Ngatena & Kapustin, 2011). Once
a patient has been diagnosed with pre-diabetes, HbA1c can be used to trend and monitor changes and
improvements in glycemic control as it accurately reflects a patient’s average plasma glucose levels over a
period of three to four months (ADA, 2012; Olson et al., 2010).
Evaluation of the ADA Clinical Practice Recommendations
Evidence-based CPGs are systematically developed assertions intended to assist clinicians in
making informed making health care decisions (AGREE Next Steps Consortium, 2009; Brouwers,
Makarski, & Levinson, 2010). Clinical practice guidelines can also have a significant impact on health
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care policy (Brouwers et al., 2010). The “Standards of Medical Care in Diabetes-2012” is the ADA’s most
recent CPG. This document is reviewed and updated annually and also serves as the ADA’s all-inclusive
position statement (ADA, 2012).
The AGREE II Instrument was used to assess the global quality, methodological rigor, and
transparency of the “Standards of Medical Care in Diabetes-2012.” The purpose of this instrument is to
provide a uniform approach and framework for assessing the quality of CPGs (AGREE Next Steps
Consortium, 2009). It is comprised of 23 criteria that assess CPGs according to six domains including
scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability,
and editorial independence (AGREE Next Steps Consortium, 2009; Brouwers et al., 2010). A seven point
likert scale, anchored with “1: strongly disagree” and “7: strongly agree,” was used to measure the extent to
which each of the criteria are met by the CPG.
The “Standards of Medical Care in Diabetes-2012” was evaluated by three board certified nurse
practitioners that routinely encounter patients with pre-diabetes in their daily practice. In general, the
ADA’s CPG was considered a quality guideline receiving a 15 out of 21 (71%) on the overall assessment.
The guideline received the highest score in Domain 1 with 60 out of 63 (95%), which appraises the
reporting of the scope and purpose of the guidelines and the clarity of presentation of the guidelines and
their lowest score in Domain 5 with 32 out of 84 (38%), which assesses the applicability of the guidelines.
Although there is no recommended monitoring or benchmarking criteria presented in the CPG, it was
found to be a quality guideline and is recommended for use. Table 4 provides information regarding the
overall assessment and domain scores for the “Standards of Medical Care in Diabetes – 2012” using the
AGREE II Instrument.
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Table 4
Assessment of ADA Clinical Practice Guidelines Using AGREE II
Domain/Area

Evaluator Evaluator Evaluator Total Score %
1
2
3

Best Possible
Score

Domain 1:
21 (100%) 20 (95%) 19 (90%)
60 (95%)
63
Scope and Purpose
Domain 2:
18 (85%) 18 (85%) 19 (90%)
55 (87%)
63
Stakeholder
Involvement
Domain 3:
48 (86%) 48 (86%) 51 (91%)
147 (88%)
168
Rigor of Development
Domain 4:
20 (95%) 19 (90%) 19 (90%)
58 (92%)
63
Clarity of Presentation
Domain 5:
7 (25%)
12 (43%) 13 (46%)
32 (38%)
84
Applicability
Domain 6:
11 (79%) 11 (79%) 11 (79%)
33 (79%)
42
Editorial Independence
Overall Assessment
5 (71%)
5 (71%)
5 (71%)
15 (71%)
21
(Scale of 1-7)
Yes
Yes
Yes
Yes
Recommended for Use? Yes
Note. Adapted from “The AGREE II Instrument” by AGREE Next Steps Consortium, 2009, retrieved from
http://www.agreetrust.org. Copyright 2009 by the AGREE Research Trust.

Analysis of Individual Studies
The disease trajectory for pre-diabetes indicates that approximately one quarter of patients will
progress to type 2 diabetes within three to five years and up to 83% of patients with pre-diabetes will
develop overt diabetes (Nathan et al., 2007). There is compelling evidence from several clinical trials and
meta-analyses that this course can be changed. Pharmacologic intervention with metformin combined with
LSM can prevent or delay the progression to diabetes (ADA, 2012; Gillies et al., 2007; Knowler et al.,
2002; Lily & Godwin, 2009; Salpeter, 2008; Yuen et al., 2010). The data supporting this relationship are
outlined in Table 5 and Table 6.
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Table 5
Characteristics of Meta-Analyses and RCTs Investigating Metformin
Author
(Date)
Knowler et
al. (2002)

Design
RCT
Seminal
study

Gillies et al.
(2007)

Metaanalysis

Salpeter
(2008)

Metaanalysis

Lily &
Godwin
(2009)

Metaanalysis

Sample

Outcome

Intervention

Results

Limitations

LSM and treatment
with metformin
reduced the incidence
of diabetes. LSM
was more effective
than metformin.
LSM and
pharmacological
interventions slowed
the progression to
type 2 diabetes.
Improvements in
weight, lipid profiles,
fasting glucose
levels, and insulin
resistance noted.
Patients treated with
metformin had a 40%
decrease in the
progression to
diabetes
Metformin was
effective in delaying
the progression to
diabetes.

Did not take into
account relative
contribution of
LSM in reduction
of diabetes.

3,234 participants
from 27 clinical
centers around U.S.
who were overweight
and had pre-diabetes.

Development
of type 2
diabetes

RCTs that evaluated
interventions to delay
type 2 diabetes in
participants with
IGT.
RCTs that compared
metformin with
placebo or no
treatment.

Development
of type 2
diabetes

Four groups:
1. LSM
2. Metformin
twice a day
3. Control
4. Troglitazone
No intervention,
meta-analysis of
17 RCTs

Development
of type 2
diabetes

No intervention,
meta-analysis of
31 RCTs

RCTs involving
administration of
metformin to prevent
diabetes in subjects
with IFG/IGT.

Development
of type 2
diabetes

No intervention,
meta-analysis of
3 RCTs

Used Jadad
scoring to rate
RCTs however no
explanation of
tool.
No discussion of
tool or instrument
used to rate
studies.

No use of
electronic
databases for
search with
overlap of some
articles.
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Author
(Date)
Yuen,
Sugeng, &
Weiland
(2010)

Design
Metaanalysis

Sample

Outcome

Intervention

Results

Limitations

RCTs that followed
Development
No intervention, Oral hypoglycemic
Internal validity of
participants for one
of type 2
meta-analysis of and anti-obesity
instrument used to
year. Studies
diabetes
4 RCTs
agents reduce the
assess studies for
compared
incidence of diabetes. inclusion.
intervention with oral
hypoglycemic and
anti-obesity agents.
Note. Adapted from Evidence Based-Practice in Nursing and Healthcare (2nd ed.) (p. 515-516) by B. M. Melnyk and E. FineoutOverholt, 2011, Philadelphia, PA: Lippincott Williams & Wilkins. Copyright 2011 by Wolters Kluwer Health Lippincott Williams
&Wilkins.
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Table 6
Characteristics of Clinical Trials Evaluating the LSM and Medication
Trial/Year
Pan, 1997

Location
China

Population
n=530 with IGT

Age/Gender
>25 years
283 men/247 women

Interventiona
LSM

Finnish
Diabetes
Prevention
Study, 1993
Japanese
Diabetes
Prevention,
2005
Kosaka, 2005

Finland

n=522 with IGT

AGE
33% men/67% women

LSM

Japan

n=240 with IGT

Mean Age=51
51% men/49% women

Japan

n=356 with IGT

Liao, 2002

U.S.

Wein, 1999

Australia

Conclusion
LSM decreases the
incidence of diabetes
among those with
IGT.
LSM reduced diabetes
risk.

Criteria
WHO
1985

LSM

LSM is useful in
preventing diabetes in
Japanese with IGT.

WHO
1999

Age 30-70
100% men

LSM

WHO
1980

n=70 with IGT

Mean Age 55.8
45% men/55% women

LSM

n=200 with
history of GDM
and IGT

Age 38-40
100% women

LSM

LSM aimed at
achieving ideal body
weight in men with
IGT is effective.
LSM may prevent
diabetes in Japanese
Americans with IGT
Incidence rates of
diabetes mellitus were
lower with metformin
than control group.

WHO
1985

WHO
1998
WHO
1985
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Trial/Year
EDIT, 2003

Age/Gender
Age 30-70
49% men/51% women

Interventiona
M

Conclusion
Criteria
Risk of diabetes not
WHO
reduced with
1985
metformin or
combination therapy.
The ability of
therapies to reduce
risk of diabetes may
differ for those with
IGT or IFG.
Li, 1999
China
n=90 with IGT
Age 30-60
M
Metformin reduces the WHO
rate of type 2 diabetes. 1985
Diabetes
U.S.
n=3234 with
Age > 25
B
LSM and treatment
ADA
Prevention
IGT
33% men/68% women
with metformin
1997
Program, 2002
reduced the incidence
of diabetes.
Indian
India
n=531 with IGT Age 35-55
B
LSM and metformin
WHO
Diabetes
79% men/21% women
reduced the incidence 1999
Prevention
of diabetes in Asian
Program, 2006
Indians with IGT;
there was no added
benefit from
combining them.
Note. Adapted from “Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose
tolerance” by Gillies et al., 2007, British Medical Journal, 334, pp. 2-3. Copyright 2012 by BMJ Publishing Group Limited.
a
Intervention abbreviations – LSM=lifestyle modification, M=metformin, B=LSM and metformin
.

Location Population
UK
n=631, some
with IGT
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Randomized Control Trial: Seminal Study
The Diabetes Prevention Program Research Group (DPP) conducted a seminal study
regarding the management of patients with pre-diabetes in the United States. This landmark,
multicenter RCT evaluated the effect of pharmacotherapy with metformin and LSM on the
development of type 2 diabetes in 3,234 obese participants with pre-diabetes (Knowler et al.,
2002). In the DPP, participants from 27 clinical sites in the United States were randomly
assigned to one of four different interventions: LSM, metformin, troglitazone, and placebo or
control. The troglitazone portion of the study was discontinued prior to the completion of the
study, because troglitazone was discovered to cause liver damage.
The goal for participants assigned to the LSM segment of the DPP was moderate weight
loss through improved nutrition and increased physical activity. Participants in LSM group
partook in a 16-week curriculum covering exercise, nutrition, and behavior modification
strategies while participants assigned to the metformin group received 850 mg of metformin
twice daily. The LSM group experienced a 58% (95% Confidence Interval [CI], 48-66)
reduction in the risk of developing diabetes and the metformin group experienced a 31% (95%
CI, 17-43) reduction in the risk of developing diabetes (Knowler et al., 2002). Metformin was
maximally effective in participants from ages 25 to 44 years and those who were at least 60
pounds overweight (Knowler et al., 2002).
The results of the DPP are significant and imply that LSM and pharmacotherapy with
metformin are useful in the prevention of diabetes. Participants in both the LSM and metformin
groups experienced lower rates of progression to overt diabetes as compared to 11% for those
participants assigned to the placebo or control group. These findings were true for both genders
and across all ethnic groups included in the study (Knowler et al., 2002).
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Meta-Analyses
Gillies et al. (2007) performed a meta-analysis of RCTs that examined the efficacy of
lifestyle and pharmacologic interventions designed to delay or prevent type 2 diabetes in patients
with IGT. A total of 17 trials from 1979 to 1996 with 8,084 participants were included. Based
on the time period covered in the meta-analysis, multiple diagnostic criteria for type 2 diabetes
and IGT were used. Most diagnostic criteria for type 2 diabetes however, were analogous, as
they required a plasma glucose level of ≥11.1 mmol/l on the 2 h OGTT and a FPG concentration
of ≥7.8 mmol/l. The criterion used to define IGT was 7.8-11.1 mmol/l on the 2 h OGTT.
Gillies et al. (2007) performed four meta-analyses on studies targeting LSM and
pharmacologic interventions. Each meta-analysis yielded evidence that LSM and pharmacologic
intervention can successfully prevent or delay the onset of type 2 diabetes. A comprehensive
meta-analysis of LSM employed revealed a pooled hazard ratio of 0.51 (95% CI, 0.44-0.60,
p<0.001) indicating a 49% relative reduction in the development of diabetes. The pooled hazard
ratio for anti-diabetic medications was 0.44 (0.28-0.69, p<0.001) for anti-diabetic medication
indicating a 56% reduction in the relative risk of developing diabetes.
The RCTs included in the meta-analysis by Gillies et al. (2007) were heterogeneous in
terms of interventions applied, ethnicity, weight, and age. The meta-analysis of LSM identified
no reporting or publication bias (Begg’s test p=0.945 and Egger’s test p=0.340). Reporting
biases however, may have limited the assessment of the efficacy of anti-diabetic medications in
reducing or delaying the onset of type 2 diabetes (Begg’s test p=0.012 and Egger’s test p=0.058).
A similar meta-analysis by Yuen et al. (2010) included a total of four RCTs. The number
of subjects in the included studies ranged from 178 to 3,234. The primary outcome measure for
each RCT was the diagnosis of type 2 diabetes according to the 2h OGTT. The criteria used to
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define type 2 diabetes however, varied from study to each study. The ADA criterion for type 2
diabetes was used in one study, and the WHO criteria were used in three. The overall risk of
bias in the four studies was high. Based on the evidence presented in each study, the authors did
not speculate as to which intervention was more effective in preventing type 2 diabetes. The
authors however, concluded that LSM and pharmacologic intervention with metformin slow the
onset of type 2 diabetes in patients with pre-diabetes.
Lily and Godwin (2009) conducted a meta-analysis of RCTs that evaluated the efficacy
of metformin in preventing the onset of type 2 diabetes in patients with IFG or IGT. Incident
diabetes was a required outcome measure; follow-up time of a minimum of six months was also
required. A total of three RCTs from 1999 to 2002 with 42,932 participants from India, China,
and the United States were included. The metformin dosage administered and the rate of
progression to diabetes varied across the RCTs. This meta-analysis revealed that regardless of
gender or ethnicity, study participants who were treated with metformin experienced a lower rate
of conversion from pre-diabetes to diabetes (Odds Ratio [OR] 0.65, 95% CI, 0.55-0.78,
p<.00001). These findings support the hypothesis that pharmacotherapy with metformin delays
the onset of type 2 diabetes in patients with pre-diabetes.
A recent meta-analysis by Salpeter (2008) showed that metformin is beneficial in the
treatment of pre-diabetes. This study included 31 RCTs with 4,570 patients who were monitored
for 8,267 patient years. The trials included in this meta-analysis assessed pre-diabetic patients
from various populations and ethnic backgrounds. Metformin was shown to significantly
decrease weight, improve insulin resistance, and reduce the incidence of type 2 diabetes by 40%
with a pooled OR of 0.6 (95% CI, 0.5-0.8).

20
Summary
In summary, the evidence from the clinical trials and meta-analyses demonstrates that
pharmacologic intervention with metformin combined with LSM can prevent or delay the
progression to diabetes. Many of the clinical trials included in these meta-analyses serve as the
basis of the 2012 ADA standards for patients with pre-diabetes. Due to the insidious nature of
pre-diabetes, aggressive management with LSM and medication are now cornerstones of care.
These are the standards by which the clinical management of pre-diabetes was evaluated at the
clinic for the working uninsured.
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Chapter Three: Methodology
This chapter includes a description of the design, sample, and data collection tool used
for this quality improvement project. There is also a discussion of the methods and procedures
for the project including the protection of human subjects. The purpose of this project was to
evaluate the implementation of the 2012 ADA clinical practice guidelines regarding the
management of patients with pre-diabetes by the health care practitioners at a clinic for the
working uninsured.
Study Design
This study utilized a retrospective review with a one-group post only design. Data was
collected from patient charts for the three month period between July and September 2012. This
time period was chosen because it was six months after the 2012 ADA clinical practice
guidelines were published.
Setting
The setting for this study was a volunteer-run clinic located in a large metropolitan area
in the southeastern United States. This clinic includes both physicians and nurse practitioners
who provide primary care services to uninsured, working adults and their families.
Sample
A retrospective analysis of 50 medical records were reviewed sequentially to evaluate the
implementation of the 2012 ADA clinical practice guidelines regarding the management of
patients with pre-diabetes by the health care practitioners at the clinic for the working uninsured.
Permission to conduct this quality improvement project was obtained from the investigator’s
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project committee, the Institutional Review Board (IRB) at the University of North Florida, and
the executive board of the clinic (Appendix B and Appendix C).
Methods
Data was collected for the timeframe covering July to September 2012, which was six
months after the 2012 ADA clinical practice guidelines were published. Charts for this study
were identified by the clinic staff including individual providers, the chief information officer,
and the clinical and medical directors. Potential charts for this study were also identified using a
search according to diagnosis and International Classification of Disease Ninth Edition Clinical
Modification (ICD-9-CM) codes. Diagnoses that were searched included pre-diabetes, IFG, and
IGT. Searches according to ICD-9-CM included 790.21, 790.22, and 790.29.
Data Collection
Data was collected for the timeframe covering July to September 2012. All data was
collected by the principal investigator and was de-identified and documented on the study data
collection sheet. The data collection sheet that was used in the study is located in Appendix D.
After potential charts were identified, the following steps were taken during this project to
collect the data:
1. All charts remained at the clinic.
2. Each chart was assigned a unique study “n” number different from the patient
identification number used in the clinic. The purpose of the “n” study number
was to assist the principal investigator in tracking the total number of charts that
were reviewed during the study.
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3. Each chart was verified to ensure that the patient was over the age of 18. If there
was evidence in the chart that the patient was under the age of 18, the chart was
excluded from the study.
4. Each chart was reviewed to verify a diagnosis of pre-diabetes according to the
2012 ADA criteria. If there is no was no evidence of a diagnosis of pre-diabetes
according to the ADA 2012 criteria in the patient chart, it was excluded from the
study (see data collection tool, Appendix D).
5. Each chart was reviewed to verify that care for pre-diabetes was provided during
the timeframe from July to September 2012. If there was no evidence that care
for pre-diabetes was provided during that timeframe, it was excluded from the
study (see data collection tool, Appendix D).
6. All data was de-identified.
7. Demographic data included the time period or month in which care was provided
(see data collection tool, Appendix D).
8. Data collected included treatment modalities employed for the management of
pre-diabetes. These treatment modalities included no treatment, LSM,
medication, or a combination of LSM and medication (see data collection tool,
Appendix D).
Fesaibility
This project was designed to evaluate the implementation of the 2012 ADA clinical
practice guidelines regarding the management of patients with pre-diabetes by the health care
providers at a clinic for the working uninsured. The staff at the clinic is dedicated to providing
evidence-based primary care and specialty services to the community’s working uninsured. The
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clinic staff is continuously looking toward quality improvement and are willing to update and
change their practices to benefit patients. The data and results obtained from this quality
improvement project are not generalizable. The outcomes however, will provide valuable
information to the clinic staff regarding the implementation of the 2012 ADA standards of care
by the providers.
Income and Expenses
The primary expenses for this project included office supplies and printing. These
expenses were considered negligible and were incurred by the principal investigator.
Protection of Human Subjects
This study evaluated existing data from patient charts. Minimal risk was associated with
this project. A waiver of consent and a waiver of the Health Insurance Portability and
Accountability Act of 1996 (HIPAA) regulations was requested and granted by the IRB at the
University of North Florida. Risk of breach of confidentiality however, is an associated risk with
any chart review. To mitigate this risk and to ensure that the privacy and security of the data
obtained during the study, all HIPAA regulations were followed. All patient records remained at
the clinic. Additionally, no individually identifying data was collected. Data from this project
was collected and recorded on the data collection sheet and transferred to an electronic
spreadsheet (Appendix D).
Confidentiality
Data was stored in a locked file cabinet in the home office of the principal investigator.
The data was de-identified and not linked to any identifiable information from the medical
record, and used only in aggregate. Each record was assigned a unique study number which was
recorded on the data collection sheet.
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Data was entered into an electronic spreadsheet on the principal investigator’s laptop
computer, which was protected by a password. Data from the spreadsheet was uploaded into a
Statistical Package for the Social Sciences (SPSS) database. Once data collection was complete,
all data was entered, verified and analyzed, all project-related documents were destroyed.
Data Analysis Plan
All raw data entered was entered into the computer and checked for errors. Data was
analyzed using SPSS (version 21.0, 2012, Armonk, NY) with statistical significance determined
at p≤0.05. Descriptive statistics such as frequency, percentage, mean, and significance level
were used to analyze the implementation of the 2012 ADA standards of care for patients with
pre-diabetes at the clinic. Trends in the implementation of the 2012 ADA standards of care were
considered significant.
Summary
This chapter describes the methodology for this project, the permissions that were
obtained in order to conduct this quality improvement project, and the data analysis plan. Data
for this projected were collected using the timeframe covering July to September 2012. Data
collected during this project were used to evaluate provider practices regarding the management
of pre-diabetes according to the 2012 ADA standards of care. Data analysis provided valuable
information for the clinic providers regarding evidence-based practice when caring for patients
with pre-diabetes.
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Chapter Four: Results
This chapter provides a description of the sample and the disposition of the medical
records that met inclusion criteria. Sample characteristics including the time period in which
pre-diabetes care was received, treatment modality provided, and if the pre-diabetes care that
was provided met the 2012 ADA standards of care, were described using descriptive statistics
including the frequency and percentage of the variables. Analyses were executed using SPSS
statistical software (version 21.0, 2012, Armonk, NY) with statistical significance determined at
p ≤ .05.
Sample Characteristics
Fifty medical records were initially identified for inclusion in the study. Medical records
of 26 patients met the inclusion criteria and were included in the final analysis. All charts
included in the study were of patients over the age of 18 who met the ADA criteria for a
diagnosis of pre-diabetes and had care for pre-diabetes documented during the period from JulySeptember 2012. A total of 24 charts were excluded: five charts were unavailable because the
patients were no longer enrolled in the clinic; four charts did not meet the ADA diagnostic
criteria for pre-diabetes; and, 15 charts did not have care documented during the time period of
interest. Figure 1 depicts the disposition of the charts identified for inclusion in the study (see
Figure 1).
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Figure 1. Chart disposition. This figure illustrates the disposition of the charts identified for
inclusion in the study.

Time Period of Pre-Diabetes Care
The medical records reviewed had pre-diabetes care documented in each of the three time
periods representing July 2012, August 2012, and September 2012 with equal probability, 2(25,
n=26) = 0.34, p=.05. During the period covering July 2012, 12 (46.2%) records had care
documented for pre-diabetes. Eight charts (30.8%) had care for pre-diabetes documented during
the period covering August 2012, and six charts (23.1%) had pre-diabetes care documented
during the period covering September 2012. Table 7 depicts the time period in which prediabetes care was provided during the study.

Table 7
Time Period of Pre-Diabetes Care
Month
July
August
September
Total

Frequency Percent
12
46.2
8
30.8
6
23.1
26
100.0
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Treatment Modality
Eight (30.8%) of the medical records reviewed during the study had no documentation of
treatment for pre-diabetes. A total of 18 of the medical records reviewed (69.2%) had
documentation of some type of treatment for pre-diabetes documented during the study period.
One (3.8%) medical record had evidence of a combined approach using LSM and metformin to
manage pre-diabetes, while 17 (65.4%) medical records had evidence of LSM as the primary
treatment modality for pre-diabetes.
The categories of LSM documented in the medical records that were reviewed included
singular modifications such as nutrition counseling (n=6, 35.3%), increased activity or exercise
(n=1, 5.9%), weight loss (n=1, 5.9%) as well as combined adjustments including nutrition
counseling and increased activity or exercise (n=1, 5.9%), and nutrition counseling and weight
loss (n=8, 47.1%) (see Table 8). The type of LSM documented in the reviewed records occurred
with different probabilities, 2(16, n=17) = 0.010, p=.05.
Table 8
Type of LSM Documented in Records Reviewed
Type of LSM
Nutrition
Weight
Exercise
8
Nutrition + Weight
Nutrition +Exercise
Total

Frequency
6
1
1
8
1
17

Percent
35.3
5.9
5.9
47.1
5.9
100.0
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Standards of Care
Of the medical records reviewed for the study, 25 (96.2%) had no evidence that the 2012
ADA standards of care for patients with pre-diabetes was provided. This included eight (30.8%)
records that had no documented treatment for pre-diabetes and 17 (65.4%) records that had
evidence of only LSM for the treatment of pre-diabetes. One (3.8%) medical record met the
standard of care with documentation of a combined approach using LSM and metformin for the
treatment of pre-diabetes (See Figure 2).

Figure 2. Charts with evidence that standard of care was met. This bar graph compares the
number of records that met the standard of care with the number record that did not meet the
standard of care.
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Summary
This chapter provided a description and discussion of the characteristics of the medical
records that were reviewed during this study. It describes the study outcomes according to the
time period that pre-diabetes care was provided and the treatment modality prescribed. A
comparison of the prescribed treatment modality documented in the medical records according to
the 2012 ADA standards of care is also made in this chapter.
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Chapter Five: Discussion
This chapter provides a discussion of the project outcomes relevant to the practitioners’
use of clinical practice guidelines for patients with pre-diabetes. This discussion is followed by
the limitations of the study. Implications for evidence-based practice and recommendations for
future projects are also presented.
Discussion
Pre-diabetes is one of the most common conditions encountered in primary care. Nearly
one quarter of adult patients over the age of 20 have pre-diabetes (CDC, 2011; Cowie et al.,
2009). There is compelling evidence that early identification and aggressive treatment of
persons with pre-diabetes with metformin and LSM can slow or prevent disease progression
(ADA, 2012; Gillies et al., 2007; Knowler et al., 2002; Lily & Godwin, 2009; Salpeter, 2008;
Yuen et al., 2010).
The purpose of this project was to evaluate the implementation of the 2012 ADA clinical
practice guidelines regarding the management of patients with pre-diabetes by the health care
providers at a clinic for the medically uninsured. Specifically, this project evaluated if the health
care providers at the clinic implemented the 2012 ADA standards of care when managing
patients with pre-diabetes using LSM, medication, or a combination of both. The desired
outcome was that the health care providers treated patients with pre-diabetes according to the
2012 ADA standards of care and used a combined approach of LSM and medication. Although
majority of records reviewed in this study had documentation of LSM as the primary treatment
modality for pre-diabetes, only one medical record reviewed during this study met the 2012
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ADA standards of care. These results suggest that in the charts reviewed for this study that the
providers at the clinic were not following the 2012 ADA standards of care.
When examining the time periods when pre-diabetes care was provided, it was expected
that during each successive month a greater percentage of charts would meet the 2012 ADA
standards of care. The medical records reviewed in this study were evenly distributed across the
three time periods of care. The only medical record that met the 2012 ADA standards of care,
however, had pre-diabetes care documented during July 2012, the first period of care.
Limitations
There were many limitations to this project that should be noted. These include sample
size, study design, and study setting. The project design was chosen because it was a good fit
based on the time constraints and setting where this quality improvement project was conducted.
This study utilized a retrospective review with a one-group post only design. A onegroup post-only design does not provide baseline information for comparison, nor does it
account for extraneous influences that may have an effect on the dependent variable. A onegroup pretest-posttest design is a more suitable option in future studies. This design provides
baseline information that measures the effect by examining the difference between the pretest
and posttest scores.
Another limitation to the study was the small sample size. The final sample included a
convenience sample of 26 medical records. For this reason, the findings from this study cannot
be generalized to the broader community. The small sample size and the demographic
information collected also precluded any complex statistical evaluation. Future quality
improvement projects utilizing medical records reviews to evaluate clinical practice should
perform an ongoing review with a larger, more robust sample. With an expected attrition of
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approximately 50% of the medical records, there would be a more realistic approximation of a
normal distribution.
This study was conducted at only one institution in a large metropolitan area in the
southeastern United States. The clinic has a unique provider base and serves a specialized
population. Most of the primary care providers at the clinic are volunteers and many of the
providers are retired. The clinic serves working uninsured patients and their families. This study
requires replication in settings with paid providers as well as in settings with insured patients.
Implications for Practice
The results of this project highlight some of the complex issues associated with
implementing evidence-based practice changes. Evidence-based practice requires healthcare
providers to synthesize and apply credible evidence to individual patient situations while using
their clinical judgment and considering the patient’s values and resources (Melnyk & FineoutOverholt, 2011). Implementing evidence-based clinical practice guidelines also requires a
concerted effort from the leadership and individual providers. Although some providers may
follow evidence-based guidelines, a large majority of providers do not subscribe to them.
It is recommended that the clinic identify a clinical area such as pre-diabetes to promote
best practice and the implementation of the 2012 ADA clinical practice guidelines. Adoption of
the 2012 ADA clinical practice guidelines has the potential to improve patient outcomes.
Treating patients according to the 2012 ADA standards of care will also ensure that the providers
at the clinic are delivering standardized, high-quality care in a cost-effective manner.
Recommendations
The strategic plan at the clinic includes improving the health of the community through
education and preventative medicine. The adoption of the 2012 ADA clinical practice guidelines
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for patients with pre-diabetes fits into this strategic plan. The leadership, the providers, and the
support staff at the clinic need to be involved in future projects.
With a few modifications, this project could easily be reproduced in the clinic. An
educational program regarding pre-diabetes could be created for patients and providers. This
program would provide disease specific information and would focus on the importance of
treating pre-diabetes according to the 2012 ADA clinical practice guidelines. Early
identification and aggressive treatment of pre-diabetes has the potential to delay disease
progression and the development of type 2 diabetes.
Conclusion
Pre-diabetes remains a serious health problem in the United States. The presence of prediabetes significantly increases the risk of type 2 diabetes. Management of patients with prediabetes according to the 2012 ADA standards of care has the potential to delay the onset of type
2 diabetes and its associated comorbidities. The challenge is motivating health care providers to
implement evidence-based practice changes and use clinical practice guidelines.
Even with a small sample size, this study revealed that the providers did not use the 2012
ADA clinical practice guidelines. Clinical practice guidelines such as the 2012 ADA standards
of care promote health care interventions that have proven benefits. Clinical practice guidelines
improve the consistency of care provided to patients. The greatest benefits of implementing
clinical practice guidelines for patients with pre-diabetes include early diagnosis and aggressive
disease management. This would improve patient outcomes and, in the long run, decrease the
cost of medical care.
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Appendix A: Critical Analysis Table: Review of Meta-analyses
Question

Lily & Godwin.
(2009)
Yes
Yes

Salpeter.
(2008)
Yes
Yes

Yuen, Sugeng, &
Weiland. (2010)
Yes
Yes

Will the answer if true, have a direct bearing on the health of patients?
Is the outcome or topic something that patients/clients/population groups
would care about?
Is the problem addressed in the review one that is relevant to practice?
Yes
Yes
Yes
Will the information, if true, require a change in practice?
Yes
Yes
Yes
Was the question for the review clearly focused and appropriate?
Yes
Yes
Yes
Was the search strategy used to locate relevant studies comprehensive?
Yes
Yes
Yes
Were the databases searched and the search terms used described?
Were explicit methods used to select studies for the review? Were
Yes
Yes
Yes
inclusion/exclusion criteria specified? Were selection methods unbiased?
Was there an appraisal of the quality/validity of studies included in the
Yes
Yes
Yes
review? Were appraisal methods specified, appropriate, and reproducible?
Were specific treatments/interventions/exposures described? Were
Yes
Yes
Yes
treatments similar enough to be combined?
Was the outcome of interest clearly indicated? Were other potential harms
Yes
Yes
Yes
and benefits considered?
Were processes for data abstraction, synthesis, and analysis described?
Yes
Yes
Yes
Were they applied consistently? Was there appropriate use of qualitative
and/or quantitative synthesis? Was variation in findings among studies
analyzed? Was heterogeneity considered? If data from studies were
aggregated for meta-analysis, was the procedure described?
Are the results clearly presented in narrative? If summary statistics are used,
Yes
Yes
Yes
are levels of significance and/or confidence intervals included?
Are conclusions supported by results with biases and limitations taken into
Yes
Yes
Yes
consideration? Are limitations of the review identified and discussed?
Was bias due to the review’s funding or sponsorship unlikely?
No
No
No
Note. Adapted from Evidence Based-Practice in Nursing and Healthcare (2nd ed.) (p. 515-516) by B. M. Melnyk and E. FineoutOverholt, 2011, Philadelphia, PA: Lippincott Williams & Wilkins. Copyright 2011 by Wolters Kluwer Health Lippincott Williams
&Wilkins.
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Appendix B: Volunteers in Medicine Letter of Support for Project
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Appendix C: University of North Florida IRB Approval Letter
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Appendix D: Data Collection Sheet
Data Collection Sheet: Practitioners’ Use of Clinical
Practice Guidelines in Patients with Pre-diabetes
Study n #
Chart of patient over the age of 18?

□ Yes

□ No*

Care provided during July-September 2012 timeframe?

□ Yes

□ No*

Meets ADA 2012 definition of pre-diabetes?

□ Yes

□ No*

Criteria used to diagnose pre-diabetes, check one:
□ FPG level

□ HbA1c level

□ 2h OGTT level

Demographic Information
Time period when care was provided

□ Period 1

□ Period 2

□ Period 3

Comparable Data
Evidence of treatment for pre-diabetes

□ Yes

□ No

Lifestyle Modification

□ Yes

□ No

Type of Lifestyle Modification

□ Nutrition
□ Weight Management

Medication

□ Yes

* - Initial inclusion criteria not met, stop chart review

□ No

□ Exercise
□ Other______________
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